The estimated Net Worth of Michael Zinda is at least $3.66 Million dollars as of 28 March 2024. Dr Zinda owns over 860 units of Repare Therapeutics stock worth over $202,061 and over the last 4 years he sold RPTX stock worth over $2,867,945. In addition, he makes $585,846 as Exec. VP & Chief Scientific Officer at Repare Therapeutics.
Dr has made over 13 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 860 units of RPTX stock worth $3,999 on 28 March 2024.
The largest trade he's ever made was exercising 57,979 units of Repare Therapeutics stock on 22 December 2020 worth over $115,378. On average, Dr trades about 14,403 units every 67 days since 2020. As of 28 March 2024 he still owns at least 71,908 units of Repare Therapeutics stock.
You can see the complete history of Dr Zinda stock trades at the bottom of the page.
Dr. Michael Zinda Ph.D. is the Exec. VP & Chief Scientific Officer at Repare Therapeutics.
As the Exec. VP & Chief Scientific Officer of Repare Therapeutics, the total compensation of Dr D at Repare Therapeutics is $585,846. There are 2 executives at Repare Therapeutics getting paid more, with Lloyd Mitchell Segal having the highest compensation of $878,368.
Dr D is 50, he's been the Exec. VP & Chief Scientific Officer of Repare Therapeutics since . There are 2 older and 1 younger executives at Repare Therapeutics. The oldest executive at Repare Therapeutics Inc. is Dr. Maria Koehler M.D., Ph.D., 64, who is the Exec. VP & Chief Medical Officer.
Michael's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita, and Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Repare Therapeutics executives and other stock owners filed with the SEC include: